標(biāo)題: Titlebook: Cutaneous Biometrics; Howard Maibach,Nily Osman Living reference work 2020Latest edition clinical relevance percutaneous penetration.In v [打印本頁] 作者: FLAW 時(shí)間: 2025-3-21 16:22
書目名稱Cutaneous Biometrics影響因子(影響力)
書目名稱Cutaneous Biometrics影響因子(影響力)學(xué)科排名
書目名稱Cutaneous Biometrics網(wǎng)絡(luò)公開度
書目名稱Cutaneous Biometrics網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cutaneous Biometrics被引頻次
書目名稱Cutaneous Biometrics被引頻次學(xué)科排名
書目名稱Cutaneous Biometrics年度引用
書目名稱Cutaneous Biometrics年度引用學(xué)科排名
書目名稱Cutaneous Biometrics讀者反饋
書目名稱Cutaneous Biometrics讀者反饋學(xué)科排名
作者: GUEER 時(shí)間: 2025-3-21 20:43 作者: defibrillator 時(shí)間: 2025-3-22 01:25 作者: xanthelasma 時(shí)間: 2025-3-22 05:48
New Unionism and New Politics, 1880–1900nsiveness. Here, PDAI, ABSIS, and PVAS are presented and compared based on their measurement properties including reliability, feasibility, and correlation with anti-desmoglein using one large prospective study (n?=?100) comparing all three measures. Also, a review of additional properties including作者: flourish 時(shí)間: 2025-3-22 10:04
The Formation of a Pressure Group, 1860–80erity assessment is most commonly measured specifically through changes in facial erythema, followed by papules and pustular count and then telangiectasia. Visual inspection by a clinician is the most common modality of assessment of erythema, with a four-point scale as the most frequent methodology作者: 檔案 時(shí)間: 2025-3-22 16:43 作者: 檔案 時(shí)間: 2025-3-22 20:58
erstanding of the importance of creating meaningful dermatological patient outcome measurements and the use of the physician global assessment in a clinical setting to measure and track patient outcomes.Details978-3-319-56591-0作者: semiskilled 時(shí)間: 2025-3-22 21:42
Atopic Dermatitis Outcome Measures,ndex (DLQI) being two of the more preferred measures for eczema clinical trials, although the better of the two is yet to be decided by consensus. HOME is also making progress toward defining the core outcome measure for the long-term control domain, with future consensus meetings planned.作者: 流浪者 時(shí)間: 2025-3-23 03:18 作者: hypnogram 時(shí)間: 2025-3-23 06:00 作者: Malaise 時(shí)間: 2025-3-23 10:11 作者: confide 時(shí)間: 2025-3-23 15:12
Rosacea Severity Assessment: Review of Evaluation Methods Used in Clinical Trials,erity assessment is most commonly measured specifically through changes in facial erythema, followed by papules and pustular count and then telangiectasia. Visual inspection by a clinician is the most common modality of assessment of erythema, with a four-point scale as the most frequent methodology作者: 大都市 時(shí)間: 2025-3-23 18:33
Transcriptional Profiling Use to Improve Personalized Diagnosis and Management of Cutaneous T-Cell re upregulated in progressive disease, consistent with the notion of malignant inflammation in a pro-tumorigenic microenvironment. Furthermore, over 200 genes with known association with CTCL pathogenesis have been individually tested by RT-PCR, revealing a panel of 17 genes that can distinguish CTC作者: Devastate 時(shí)間: 2025-3-24 00:57
Living reference work 2020Latest editions biometrics and how it can be applied to their work..This book also:?.Broadens reader understanding of the importance of creating meaningful dermatological patient outcome measurements and the use of the physician global assessment in a clinical setting to measure and track patient outcomes.Details作者: AVOID 時(shí)間: 2025-3-24 03:27
Acne Severity Grading: Determining Essential Clinical Component and Features,ilitate clinical management and research, an accurate and practical method of assessing acne severity is required. Over the years, a myriad of acne global grading scales (AGGSs) have been developed. However, the lack of agreement regarding elements required for an AGGS has prevented the institution 作者: SUE 時(shí)間: 2025-3-24 08:13 作者: 博識(shí) 時(shí)間: 2025-3-24 14:45 作者: 泄露 時(shí)間: 2025-3-24 16:42 作者: 我就不公正 時(shí)間: 2025-3-24 20:32
Cutaneous Sarcoidosis Outcome Instruments: Reliability and Validity Among Dermatologists, Pulmonolots for cutaneous sarcoidosis. Cutaneous sarcoidosis outcome instruments may provide an accessible, low-cost, low-risk tool to measure disease activity and should be accessible and comprehensible to non-dermatologist investigators. The sarcoidosis activity and severity index (SASI) and the cutaneous 作者: 震驚 時(shí)間: 2025-3-25 00:49 作者: MEN 時(shí)間: 2025-3-25 03:24 作者: 流浪 時(shí)間: 2025-3-25 11:20
Pemphigus Disease Activity Measurements: Pemphigus Disease Area Index, Autoimmune Bullous Skin Dison molecules. Effective therapies can improve its devastating morbidities and mortality. Using a uniform, consensus-based and validated disease activity measure is essential to multicenter clinical trials for new therapies, meta-analysis of smaller studies, and evidence-based practice. However, above作者: Abutment 時(shí)間: 2025-3-25 12:15 作者: 沒有準(zhǔn)備 時(shí)間: 2025-3-25 18:22
Rosacea Severity Assessment: Review of Evaluation Methods Used in Clinical Trials,atient satisfaction and clinical results. Clinical trials have been executed to provide evidence-based support for the efficacy of novel rosacea treatment options. The current assessment tools used to classify the severity of rosacea in clinical trials are not standardized, limiting our ability to c作者: 宣傳 時(shí)間: 2025-3-25 23:33 作者: 額外的事 時(shí)間: 2025-3-26 01:02
Living reference work 2020Latest editioncea, wound healing, and more. Erythema of rosacea and the risk of skin ulceration associated with oral nicorandil therapy are covered in detail. Various areas of acne are addressed, including acne severity grading, the assessment of general health and quality of life in patients with acne, and the e作者: stressors 時(shí)間: 2025-3-26 07:20
Dermoepidermal Adhesion Strength Measurement Using Suction Blisters,idermis from the dermis. At the same time, fluid accumulates leading to macroscopically visible blisters. The time to blister development depends on a number of intrinsic, systemic, and local factors, and it is a direct indicator of the dermoepidermal adhesion strength. Therefore, this parameter plays a role in skin research.作者: 戰(zhàn)勝 時(shí)間: 2025-3-26 11:23 作者: Immunotherapy 時(shí)間: 2025-3-26 13:15 作者: 縮影 時(shí)間: 2025-3-26 18:11 作者: 馬籠頭 時(shí)間: 2025-3-27 00:18 作者: DEFER 時(shí)間: 2025-3-27 02:42
New Unionism and New Politics, 1880–1900The physician-reported measure was named the clinician erythema assessment (CEA), while the patient-reported measure was named the patient self-assessment (PSA). A variant of the PSA, termed the subject self-assessment (SSA), has also been created and used in subsequent clinical trials.作者: Fecundity 時(shí)間: 2025-3-27 08:02 作者: FUSE 時(shí)間: 2025-3-27 13:25 作者: 干旱 時(shí)間: 2025-3-27 15:23
Facial Erythema of Rosacea: Grading Scales,The physician-reported measure was named the clinician erythema assessment (CEA), while the patient-reported measure was named the patient self-assessment (PSA). A variant of the PSA, termed the subject self-assessment (SSA), has also been created and used in subsequent clinical trials.作者: MUT 時(shí)間: 2025-3-27 18:10 作者: 清唱?jiǎng)?nbsp; 時(shí)間: 2025-3-28 01:47
Small Bodies of the Solar System,idermis from the dermis. At the same time, fluid accumulates leading to macroscopically visible blisters. The time to blister development depends on a number of intrinsic, systemic, and local factors, and it is a direct indicator of the dermoepidermal adhesion strength. Therefore, this parameter plays a role in skin research.作者: Congregate 時(shí)間: 2025-3-28 03:00 作者: dragon 時(shí)間: 2025-3-28 06:26
http://image.papertrans.cn/d/image/241657.jpg作者: Adj異類的 時(shí)間: 2025-3-28 13:57
https://doi.org/10.1007/978-3-319-56591-0clinical relevance percutaneous penetration; In vivo nickel allergic dermatitis; transcriptional profi作者: Hippocampus 時(shí)間: 2025-3-28 18:03 作者: 偽書 時(shí)間: 2025-3-28 20:18 作者: Vertebra 時(shí)間: 2025-3-28 23:42
https://doi.org/10.1007/978-1-349-05786-3d past damage from AIBD can cause significant morbidity and negatively impact on the patient’s function. It is therefore important that the outcome measures of AIBD used in practice are objective, reliable, and specific. The development and validation of outcome measures specific to AIBD have been a作者: 膽汁 時(shí)間: 2025-3-29 04:50
Stellar Evolution and Stellar Structures,ife and are difficult to treat. Therefore, clinical trials for effective therapies to treat the skin involvement in dermatomyositis are critical. There are many validated outcome measures that allow physicians to objectively evaluate response to treatment in clinical trials and in the clinic. This c作者: 小歌劇 時(shí)間: 2025-3-29 08:07
The Origin of the Solar System,ts for cutaneous sarcoidosis. Cutaneous sarcoidosis outcome instruments may provide an accessible, low-cost, low-risk tool to measure disease activity and should be accessible and comprehensible to non-dermatologist investigators. The sarcoidosis activity and severity index (SASI) and the cutaneous 作者: Ledger 時(shí)間: 2025-3-29 11:55 作者: 斗爭 時(shí)間: 2025-3-29 18:30
New Unionism and New Politics, 1880–1900 erythema or phyma or two of the major criteria, which include flushing, papules/pustules, telangiectasia, and ocular manifestations. Assessment of facial erythema is of importance given its prevalence as the most common diagnostic feature of rosacea. Both physician-reported and patient-reported mea作者: Frequency-Range 時(shí)間: 2025-3-29 21:18 作者: Anthology 時(shí)間: 2025-3-30 00:35
Power with Responsibility, 1939–51tes long-term aggressive treatment, for which systemic corticosteroid is the gold standard. However, the serious complications associated with systemic corticosteroids have led to the development of various adjuvant therapies including azathioprine, mycophenolate mofetil, methotrexate, cyclophospham
